This article describes the presence of two new forms of a thrombinlike enzyme, both with apparent molecular masses of 38 kDa, in Bothrops atrox venom. Both share the ability to cleave fibrinogen into fibrin and to digest casein. Both present identical K m on the substrate BApNA. Their N-terminal amino acid sequences are identical for 26 residues, sharing 80% homology with batroxobin and flavoxobin. Two groups of monoclonal antibodies (mAbs) raised against the purified enzyme forms recognized different epitopes of the putative corresponding enzymes present in B. atrox crude venom. On Western blotting analysis of B. atrox crude venom, mAbs 5DB2C8, 5AA10 and 5CF11, but not mAbs 6CC5 and 6AD2-G5, revealed two or more protein bands ranging from 25 to 38 kDa. By immunoprecipitation assays, the 6AD2-G5 mAb was able to precipitate protein bands of [36][37][38] B. leucurus, B. pradoi, B. moojeni, B. jararaca and B. neuwiedii crude venoms. Fibrinogen-clotting activity was inhibited when the same venom specimens were pre-incubated with mAb 6AD2-G5, except for B. jararaca and B. neuwiedii.
Introduction
The snake venom serine proteinase family includes enzymes that transform mammalian fibrinogen into fibrin fibers (1-3), activate clotting factor V (4,5) and plasma protein C (6,7), release kinins from kallikreinogen (8, 9) and cleave the complement C3 component (10) .
We have recently shown that the thrombin-like Bothrops atrox venom component from two different Amazon regions, i.e., Manaus and Tucuruí, presented distinct chromatographic profiles and capacity to clot fibrinogen. The thrombin-like activity was isolated as a 32-kDa protein which was recognized and neutralized by horse hyperimmune serum anti-Bothrops whole venom (11) .
In this article, we present data indicating that highly purified B. atrox thrombin-like preparations contain at least two forms of the enzyme. Both clot purified bovine fibrinogen and hydrolyze a synthetic substrate, although exhibiting small differences in their molecular masses and in binding affinity for ion-exchange resins. Moreover, the enzymes share 80% N-terminal sequence homology with the thrombin-like enzyme described for B. moojeni (12) . We also describe monoclonal antibodies able to recognize and efficiently neutralize the thrombin-like enzymes of the B. atrox snake group but not able to discriminate between the two forms of thrombin-like activity.
Material and Methods

Venoms, resins and reagents
Bothrops atrox venom was provided by the Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil. This snake colony was originally started with specimens captured in Tucuruí, Pará, Brazil. Venom was filtered through a 0.45-µm membrane, lyophilized, divided into 10-mg aliquots and stored at -20 o C.
Sephacryl S-100-HR and cyanogen bromide-activated Sepharose-4B were purchased from Pharmacia Fine Chemicals (Uppsala, Sweden) and the HPLC column DEAE-5PW was purchased from BioRad Laboratories (Hercules, CA, USA). Bovine fibrinogen type IV, EDTA, and the synthetic substrates N(-benzoyl-L-arginine-p-nitroanilide (BApNA), N-succinyl-Ala-Ala-ProLeu-p-nitroanilide, N-succinyl-Ala-Ala-ProPhe-p-nitroanilide and other reagents were purchased from Sigma Chemical Co. (St. Louis, MO, USA). The molecular weight markers illustrated in Figure 3 were 66 kDa (bovine serum albumin), 45 kDa (egg albumin), 29 kDa (carbonic anhydrase), 18 kDa (ß-lactoglobulin), and 14 kDa (lysozyme) from Sigma. The Mid-Range Protein Molecular Weight Markers from Promega Corporation (Madison, WI, USA) are listed in Figures 4 and 5.
Purification of fibrinogen-clotting activity from B. atrox venom Venom samples of 50 mg dry weight were dissolved in 2.5 mM Tris-HCl buffer, pH 7.5, plus 150 mM NaCl and centrifuged to remove insoluble particles. The supernatant was applied to a Sephacryl S-100-HR (2.5 x 67 cm) column equilibrated with the same buffer. The flow rate was 1.3 ml/min and fractions of 2.5 ml were collected. Each fraction was assayed for fibrinogen-clotting activity and protein concentration was monitored at 280 nm. The fractions containing fibrinogen-clotting activity were pooled, concentrated by lyophilization and dialyzed against 2.5 mM Tris-HCl buffer, pH 7.5. The pooled activity was applied to an HPLC anion-exchange column (DEAE-5PW, BioRad) equilibrated with 2.5 mM Tris-HCl buffer, pH 7.5. Elution was performed with an NaCl gradient. The resulting fractions were assayed for fibrinogen-clotting activity and protein concentration was monitored at 280 nm. Two pools containing fibrinogenclotting activity were obtained. The pools were named TLE1 and TLE2 (thrombin-like enzyme), concentrated by lyophilization, dialyzed against 2.5 mM Tris-HCl buffer, pH 7.5, and stored at -20 o C.
Fibrinogen-clotting assay
Clotting time was determined by mixing 50 µl of the sample to be tested with 400 µl of purified bovine fibrinogen (2 mg/ml), 25 mM Tris-HCl buffer, pH 8.0, plus 150 mM NaCl at 25 o C. A unit of fibrinogen-clotting enzyme was arbitrarily defined as the amount of enzyme preparation capable of coagulating the fibrinogen solution in 1 min.
Enzyme assays and determination of kinetic parameters
Thrombin-like enzyme activity on p-nitroanilide substrates was assayed in 50 mM Tris-HCl, pH 8.0, at room temperature. The reaction was performed in a volume of 0.5 ml and was started by adding the enzyme at a final concentration of 4.0 µg/ml. Substrate hydrolysis was monitored by measuring the increase in absorbance at 410 nm. For the determination of Michaelis constant (K m ) and catalytic constants (k cat ), at least 7 substrate concentrations were used. K m and k cat were calculated according to Aguiar et al. (13) . The following p-nitroanilide substrates were used: BApNA, N-succinyl-Ala-AlaPro-Leu-p-nitroanilide and N-succinyl-AlaAla-Pro-Phe-p-nitroanilide. To determine the effect of monoclonal antibodies on the enzyme activity, appropriate dilutions of each antibody were incubated with the enzyme preparations for 30 min in 50 mM Tris-HCl, pH 8.0, followed by the addition of 120 mM of substrate. BApNA hydrolysis was recorded by the absorbance change at 410 nm. Inhibition activity was calculated on the basis of at least 5 experiments and is reported as percent.
N-terminal sequence determination
N-terminal sequences of the purified proteins were analyzed on a Shimadzu PPSQ-10 Automated Protein Sequencer by Edman degradation. PTH-amino acids were detected at 269 nm after separation on a reverse phase C18 column (4.6 x 250 mm) under isocratic conditions according to manufacturer instructions. Sequence homology and alignments were determined using the BLAST NCBI algorithm (14) .
Monoclonal antibody (mAb) production
BALB/c mice were immunized with TLE2 both before (mAbs: 6AD2-G5, 6CC5) and after SDS-PAGE separation (mAbs: 5BA9, 5DB2C8, 5AA10, 5CF11, 5DC2) using Al(OH) 3 as adjuvant. Sixteen days later a booster injection was applied with the corresponding antigens without adjuvant. Spleen cells were harvested on day 30 and fused with NSO myeloma cells according to Köhler and Milstein (15) . The supernatants of hybrid cells were screened by ELISA or Western blot methods. These supernatants were also screened for the ability of mAbs to block the fibrinogen-clotting activity present in total B. atrox venom or in purified thrombin-like preparations.
Immunoprecipitation
Twenty mg of CNBr-activated Sepharose-4B was equilibrated with 0.5 M HCl and 0.5 M NaCl, pH 2.0, for 30 min. After washing the gel with 100 mM carbonate buffer, pH 9.0, containing 0.5 M NaCl, 20 mg of mAb was added. The mixture was then incubated under gentle shaking for 4 h at room temperature, followed by 16 h at 4 o C. The gel was washed with 10 mM Tris-HCl buffer, pH 8.0, containing 0.1 M NaCl, 0.1% sodium azide and 0.1% Nonidet P40, followed by the addition of the antigen. The mixture was incubated at 37 o C for 1 h. The gel was washed with the same buffer, centrifuged and resuspended in 50 µl of SDS-PAGE sample buffer, boiled at 100 o C for 10 min, and applied to a 12% polyacrylamide gel. Protein bands were detected by Coomassie blue.
Results
B. atrox venom was fractionated on
Sephacryl S-100-HR and the fibrinogen-clotting activity was assayed. The fibrinogenclotting activity reached its maximum at the elution volume of 190 ml ( Figure 1A ), in a region where the caseinolytic hydrolysis was low ( Figure 1B) , suggesting that the observed fibrinogen-clotting activity is a specific proteolytic activity not able to hydrolyze casein.
Fractions containing more than 10 units/ ml of fibrinogen-clotting activity were pooled (Sephacryl pool), concentrated and applied to a DEAE-5PW HPLC anion-exchange column eluted with an NaCl gradient. Two protein peaks presenting fibrinogen-clotting activity were eluted and denoted TLE1 and TLE2, as Figure 1A ) was applied to a DEAE-5PW (BioRad) HPLC column, equilibrated with 2.5 mM Tris-HCl, pH 7.5, and eluted with an NaCl gradient. Absorbance was monitored at 280 nm. Thrombin-like activity (filled circles) was estimated as described in Material and Methods. Peaks 1 and 2 were pooled as indicated by bars and are denoted TLE1 and TLE2. Elution volume (ml) indicated in Figure 2 . Table 1 shows a summary of the purification steps, resulting in an enrichment of 37-fold with 7% recovery of activity in relation to crude venom. The electrophoretic profile of B. atrox crude venom and TLE1 and TLE2 after purification is shown in Figure 3 . The TLE1 and TLE2 proteins resulting from the ion-exchange step appear as bands of 38 kDa. Computed densitometric analysis (16) was used to estimate the extent of homogeneity as 95% for both proteins, indicating the existence of minor contaminants with a molecular mass of about 30 to 32 kDa. Table 2 shows that both enzymes presented a similar kinetic behavior. TLE1 and TLE2 K m for BApNA were not significantly different, and both enzymes failed to hydrolyze efficiently the other substrates used. Among the synthetic substrates used to assay the enzymatic activities of TLE1 and TLE2, BApNA was the one most rapidly hydrolyzed (Table 2 ) and was used in the inhibition experiments. The enzymatic activity of TLE1 was significantly blocked by 1 mM PMSF (28% inhibition) and by 10 µg of the mAb 6AD2-G5 (53% inhibition). The enzyme was insensitive to 0.001 mM pepstatin, 10 mM EDTA and 0.01 mM E-64 (data not shown). When tested with the same inhibitors, TLE2 presented identical behavior, supporting the conclusion that TLE1 and TLE2 are serine proteinases.
The first 26 N-terminal amino acid residues of both TLE1 and TLE2 are identical (Table 3) . When compared with published sequences for related proteins, homology was observed to be around 80% with batroxobin (12) and flavoxobin (17) . The apparent inability of mAb 6AD2-G5 ( Figure 4 , lane 7) to react with electrotransferred crude venom proteins could be attributed to the denaturating conditions used in Western blotting. We hypothesize that mAb 6AD2-G5 may be directed at a conformational rather than a structural epitope. If this were the case, its conformation could be disarranged during the Western blotting procedure. To test this hypothesis, mAb 6AD2-G5 was immobilized on CNBr Sepharose-4B and used to immunoprecipitate the specific antigens present in whole B. atrox venom. Under these conditions, the epitope recognized by mAb 6AD2-G5 was preserved and 36-38-kDa protein bands were detected in B. leucurus, B. pradoi, B. jararaca, B. neuwiedii, B. moojeni, and B. atrox venom ( Figure 5 ). The fibrinogen-clotting activity present in these venoms, but not in B. jararaca or B. neuwiedii venoms, was extensively blocked when samples were pre-incubated with mAb 6AD2-G5 ( 4.6 ± 0.5 1.9 4.1 N-S-Ala-Ala-Pro-Leu-pNA NDA --N-S-Ala-Ala-Pro-Phe-pNA ND -- Table 4 -Inhibition of fibrinogen-clotting activity by mAb 6AD2-G5.
The amount of venom or purified thrombin-like enzyme (TLE1) preparation used in the assay is given in parentheses. The fibrinogen-clotting activity (FCA) was measured as described in Material and Methods. Before addition of bovine fibrinogen solution, the venom or purified TLE1 was incubated with mAb 6AD2-G5 for 10 min at 37 o C. The IC 50 assay was performed with several concentrations of mAb 6AD2-G5 in order to estimate the mAb concentration necessary to inhibit 50% of the fibrinogen-clotting activity. 
Discussion
Edema and pain are the earliest local symptoms following injection of Bothrops venom into the victims skin. Thereafter, leukocyte infiltration, hemorrhage and intravascular thrombus formation may sometimes lead to severe tissue destruction (18) . Hypotension, blood incoagulability with intense fibrinogen consumption and respiratory distress are concurrent systemic symptoms. Depending on the amount of venom injected, kidney failure and death are possible outcomes (19) .
The snake venom serum proteases through their fibrinogen-converting activities (2), blood clotting factor V and protein C-activating enzymes (4-6), and C3-converting enzymes (10) are probably the most important mediator inducers of the tissue damage and symptoms provoked by Bothrops venoms.
The purification and characterization of two new forms of thrombin-like enzyme were reported here. Fibrinogen-clotting activities were concentrated into two closely related fractions, called TLE1 and TLE2, after serial chromatography on Sephacryl S-100-HR and DEAE-5PW. These fractions together, although representing only 7% of the total activity contained in the starting crude venom, have high specific activity (3100 U/mg) corresponding to 37 times purification (Table  1) . Both enzymes are almost equally active on synthetic specific substrates such as BApNA, suggesting that their active enzymatic sites are functionally similar. The capacity of TLE1 to hydrolyze the synthetic substrate was efficiently inhibited by mAb 6AD2-G5.
The purified proteins have similar molecular masses of 38 kDa (Figure 3 ). When amounts above 10 µg of TLE1 or TLE2 are submitted to SDS-PAGE (15%), a second band with a molecular mass of approximately 32 kDa becomes visible probably corresponding to the thrombin-like enzyme previously described by Cavinato et al. (11) . These data, and the distinct elution profiles exhibited by the two enzymes (TLE1 and TLE2) on DEAE-5PW ion-exchange chromatography strongly suggest that although they contain similar enzymatic active sites they are distinct molecules. As the amino acid sequencing data presented in this paper did not extend beyond residue 26, differences in the primary structure could be present beyond this residue. Alternatively, the molecular differences between the two enzymes could be ascribed to the extent of glycosylation of their respective polypeptide chains. This possibility is likely since thrombin-like enzymes exhibiting microheterogeneity due to differences in their polypeptide chain glycosylation have been reported in venoms from Agkistrodon rhodostoma (20, 21) Crotalus horridus horridus (22) , Lachesis muta muta (23) , Bothrops jararaca (24) and Bothrops jararacussu (25) .
The N-terminal sequences of the TLE1 and TLE2 proteins have a high homology, around 80%, compared to published sequences for related proteins such as batroxobin and flavoxobin (12, 19) .
Since most assayed mAbs were able to recognize and precipitate protein components present in B. atrox crude venom, it was interesting to determine if they could also block the thrombin-like component against which they were raised. In preliminary experiments, we found that such activity was exhibited only by mAbs 5DB2C8 and 6AD2-G5. The latter mAb significantly blocked the fibrinogen-clotting activity present in B. atrox (80% inhibition), B. leucurus (90% inhibition), B. moojeni (84% inhibition), and B. pradoi (94% inhibition), as well as the purified thrombin-like activity of B. atrox venom.
The ability of mAb 6AD2-G5 to efficiently neutralize the fibrinogen-clotting activity only of venoms from B. atrox, B. leucurus, B. pradoi and B. moojeni supports the view that these species are highly correlated and distinct from the other Bothrops species (26) . On the other hand, the mAb
